Obseva (NASDAQ:OBSV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage currently has a $19.00 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 15.36% from the company’s previous close.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
A number of other analysts have also issued reports on OBSV. TheStreet raised Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. HC Wainwright set a $30.00 target price on Obseva and gave the stock a “buy” rating in a research report on Monday, July 16th. Wedbush assumed coverage on Obseva in a research report on Monday, August 6th. They set an “outperform” rating and a $34.00 target price on the stock. Credit Suisse Group assumed coverage on Obseva in a research report on Thursday, July 19th. They set an “outperform” rating and a $24.00 target price on the stock. Finally, Leerink Swann assumed coverage on Obseva in a research report on Wednesday, August 15th. They set an “outperform” rating and a $25.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $28.50.
Obseva (NASDAQ:OBSV) last announced its earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. As a group, research analysts predict that Obseva will post -1.93 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. DRW Securities LLC increased its holdings in Obseva by 55.0% in the second quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock valued at $512,000 after buying an additional 12,000 shares during the last quarter. Vivo Capital LLC bought a new stake in Obseva in the second quarter valued at about $14,005,000. Point72 Asset Management L.P. bought a new stake in Obseva in the second quarter valued at about $3,028,000. Laurion Capital Management LP bought a new stake in Obseva in the second quarter valued at about $2,271,000. Finally, VHCP Management II LLC increased its holdings in Obseva by 5.1% in the second quarter. VHCP Management II LLC now owns 2,252,460 shares of the company’s stock valued at $34,102,000 after buying an additional 108,617 shares during the last quarter. 68.26% of the stock is owned by hedge funds and other institutional investors.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.